Candida auris is an emerging fungus that presents a serious global health threat. CDC is concerned about C. auris for three main reasons:
- It is often multidrug-resistant, meaning that it is resistant to multiple antifungal drugs commonly used to treat Candida infections. Some strains are resistant to all three available classes of antifungals.
- It is difficult to identify with standard laboratory methods, and it can be misidentified in labs without specific technology. Misidentification may lead to inappropriate management.
- It has caused outbreaks in healthcare settings. For this reason, it is important to quickly identify C. auris in a hospitalized patient so that healthcare facilities can take special precautions to stop its spread.
CDC encourages all U.S. laboratory staff who identify C. auris to notify their state or local public health authorities and CDC at email@example.com.
- December 11, 2019: Case count updated to 941
- October 29, 2019: Updated Identification, added page for Researchers and Industry Professionals
- April 17, 2019: Updated Antifungal Susceptibility Testing and Interpretation to report the first pan-resistant U.S. cases
- March 7, 2019: Updated Tracking Candida auris to reflect 2019 nationally notifiable status and updated case definition